Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

414 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Utilising primary care electronic health records to deliver the ALABAMA randomised controlled trial of penicillin allergy assessment.
Ahmed S, Fielding J, Porter CE, Armitage KF, Wanat M, Bates C, Engonidou L, West RM, Yu LM, Galal U, Howard P, Butler CC, Savic S, Boards J, Tonkin-Crine S, Parry J, Pavitt SA, Sandoe JT; ALABAMA research team. Ahmed S, et al. Among authors: yu lm. Trials. 2024 Oct 3;25(1):653. doi: 10.1186/s13063-024-08506-x. Trials. 2024. PMID: 39363246 Free PMC article.
Low-dose spironolactone and cardiovascular outcomes in moderate stage chronic kidney disease: a randomized controlled trial.
Hobbs FDR, McManus RJ, Taylor CJ, Jones NR, Rahman JK, Wolstenholme J, Kim S, Kwon J, Jones L, Hirst JA, Yu LM, Mort S; BARACK-D Investigators; BARACK-D Investigators; Regional coordinating centre teams. Hobbs FDR, et al. Among authors: yu lm. Nat Med. 2024 Sep 30. doi: 10.1038/s41591-024-03263-5. Online ahead of print. Nat Med. 2024. PMID: 39349629
Health outcomes 3 months and 6 months after molnupiravir treatment for COVID-19 for people at higher risk in the community (PANORAMIC): a randomised controlled trial.
Harris V, Holmes J, Gbinigie-Thompson O, Rahman NM, Richards DB, Hayward G, Dorward J, Lowe DM, Standing JF, Breuer J, Khoo S, Petrou S, Hood K, Ahmed H, Carson-Stevens A, Nguyen-Van-Tam JS, Patel MG, Saville BR, Francis N, Thomas NPB, Evans P, Dobson M, Png ME, Lown M, van Hecke O, Jani BD, Hart ND, Butler D, Cureton L, Patil M, Andersson M, Coates M, Bateman C, Davies JC, Raymundo-Wood I, Ustianowski A, Yu LM, Hobbs FDR, Little P, Butler CC; PANORAMIC Trial Collaborative Group. Harris V, et al. Among authors: yu lm. Lancet Infect Dis. 2024 Sep 9:S1473-3099(24)00431-6. doi: 10.1016/S1473-3099(24)00431-6. Online ahead of print. Lancet Infect Dis. 2024. PMID: 39265595 Free article.
Favipiravir for COVID-19 in adults in the community in PRINCIPLE, an open-label, randomised, controlled, adaptive platform trial of short- and longer-term outcomes.
Hobbs FR, Gbinigie-Thompson OA, Shanyinde M, Yu LM, Harris V, Dorward J, Hayward G, Saville BR, Berry NS, Evans PH, Thomas NP, Patel MG, Richards D, Hecke OV, Detry MA, Saunders CT, Fitzgerald M, Robinson J, Latimer-Bell C, Allen J, Ogburn E, Grabey J, de Lusignan S, Andersson M, Little P, Butler CC; PRINCIPLE Trial Collaborative Group. Hobbs FR, et al. Among authors: yu lm. J Infect. 2024 Oct;89(4):106248. doi: 10.1016/j.jinf.2024.106248. Epub 2024 Aug 29. J Infect. 2024. PMID: 39216829 Free article. Clinical Trial.
414 results